Group of patients with plaque psoriasis being treated with COSENTYX
START HERE to see
what COSENTYX® can
do for your patients
DERMATOLOGY RHEUMATOLOGY SUPPORT
 
 
*Limitations apply. Up to a $16,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. For complete Terms and Conditions details, call 1-844-267-3689.
†Certain payers have carve-outs that restrict utilization of manufacturer support programs.
Reference: 1. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777-783.
 
Click or scroll down to see full Indications and Important Safety Information
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
COSENTYX® (secukinumab) is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.
Scroll down to read more
For US Healthcare Professionals Only
Please rotate your device for the best mobile experience.